Patents by Inventor Paul Joseph Gilligan

Paul Joseph Gilligan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Imidazo-triazines as corticotropin releasing factor antagonists
    Publication number: 20040023965
    Abstract: The present invention describes novel imidazo-triazines of formula I: 1
    Type: Application
    Filed: April 29, 2003
    Publication date: February 5, 2004
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
    Patent number: 6579876
    Abstract: The present invention describes novel compounds of formula (Ib): wherein D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as corticotropin releasing factor antagonists.
    Type: Grant
    Filed: February 11, 2002
    Date of Patent: June 17, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
    Publication number: 20030055059
    Abstract: The present invention describes novel imidazo-pyridines, -pyridazines, and -triazines of formula I: 1
    Type: Application
    Filed: February 11, 2002
    Publication date: March 20, 2003
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • Imidazo-pyridines as corticotropin releasing factor antagonists
    Patent number: 6521636
    Abstract: The present invention describes novel imidazo-pyridines of formula I: wherein D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as corticotropin releasing factor antagonists.
    Type: Grant
    Filed: July 25, 2000
    Date of Patent: February 18, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • 1H-imidazo[4,5-d]pyridazin-7-one, and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
    Patent number: 6518271
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: February 11, 2003
    Assignee: Bristol-Myers Squibb Company
    Inventors: Paul Joseph Gilligan, Rajagopal Bakthavatchalam
  • Arylamino fused pyridines
    Patent number: 6448261
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I; and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: September 10, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Rajagopal Bakthavatchalam, Argyrios Georgios Arvanitis, James Peter Beck, Gary Avonn Cain, Robert John Chorvat, Paul Joseph Gilligan, Richard Eric Olson
  • Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
    Patent number: 6365589
    Abstract: The present invention describes novel imidazo-pyridines, -pyridazines, and -triazines of formula I: wherein A and B can be C or N and D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: April 2, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • 1N-alkyl-n-arylpyrimidinamines and derivatives thereof
    Patent number: 6342503
    Abstract: The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer'disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R4, R5, Z, Y, V, X, X′, J, K, L, and M are as defined herein.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: January 29, 2002
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Paul Edward Aldrich, Argyrios Georgios Arvanitis, Robert Scott Cheeseman, Robert John Chorvat, Thomas Eugene Christos, Paul Joseph Gilligan, Dimitri Emil Grigoriadis, Carl Nicholas Hodge, Paul John Krenitsky, Everett Latham Scholfield, Sang William Tam, Zelda Rakowitz Wasserman
  • 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
    Patent number: 6271380
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: December 28, 1999
    Date of Patent: August 7, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Paul Joseph Gilligan, Rajagopal Bakthavatchalam
  • 6-aryloxy and arylthiopurines
    Patent number: 6258809
    Abstract: Novel compounds and pharmaceutical compositions thereof, and methods of using same in treating anxiety, depression, and other psychiatric and neurological disorders. The novel compounds provided by this invention are those of the following formulae: wherein R1, R13, X, Y, Z, G and Q are as defined herein.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: July 10, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Parthasarathi Rajagopalan, Robert John Chorvat, Rajagopal Bakthavatchalam, James Peter Beck, Paul Joseph Gilligan, Richard Eric Olson
  • Aryloxy- and arylthio- fused pyridines and pyrimidines and derivatives
    Patent number: 6124300
    Abstract: Novel compounds and pharmaceutical compositions thereof, and methods of using same in treating anxiety, depression, and other psychiatric and neurological disorders. The novel compounds provided by this invention are those of the following formulae: ##STR1## wherein R.sup.1, R.sup.13, X, Y, Z, G and Q are as defined herein.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: September 26, 2000
    Assignee: DuPont Pharmaceuticals
    Inventors: Parthasarathi Rajagopalan, Robert John Chorvat, Rajagopal Bakthavatchalam, James Peter Beck, Paul Joseph Gilligan, Richard Eric Olson
  • Azolo triazines and pyrimidines
    Patent number: 6124289
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: ##STR1## and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivityassociated with psychopathological disturbance andstress.
    Type: Grant
    Filed: July 23, 1997
    Date of Patent: September 26, 2000
    Assignee: Dupont Pharmaceuticals Co.
    Inventors: Liqi He, Paul Joseph Gilligan, Argyrios Georgios Arvanitis, Robert John Chorvat
  • 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
    Patent number: 6107301
    Abstract: The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: ##STR1## wherein R.sup.1, R.sup.3, R.sup.4, R.sup.5, Z, Y, V, X, X', J, K, L, and M are as defined herein.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: August 22, 2000
    Assignee: Dupont Pharmaceuticals Company
    Inventors: Paul Edward Aldrich, Argyrios Georgios Arvanitis, Rajagopal Bakthavatchalam, James Peter Beck, Robert Scott Cheeseman, Robert John Chorvat, Paul Joseph Gilligan, Carl Nicholas Hodge, Zelda Rakowitz Wasserman
  • Arylamino fused pyrimidines
    Patent number: 6107300
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or formula II: ##STR1## and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: August 22, 2000
    Assignee: Dupont Pharmaceuticals
    Inventors: Rajagopal Bakthavatchalam, Argyrios Georgios Arvanitis, James Peter Beck, Gary Avonn Cain, Robert John Chorvat, Paul Joseph Gilligan, Richard Eric Olson